WO2009063998A1 - 疎水性物質付加核酸及びその使用 - Google Patents

疎水性物質付加核酸及びその使用 Download PDF

Info

Publication number
WO2009063998A1
WO2009063998A1 PCT/JP2008/070822 JP2008070822W WO2009063998A1 WO 2009063998 A1 WO2009063998 A1 WO 2009063998A1 JP 2008070822 W JP2008070822 W JP 2008070822W WO 2009063998 A1 WO2009063998 A1 WO 2009063998A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
midkine
hydrophobic substance
substance added
nanoparticle
Prior art date
Application number
PCT/JP2008/070822
Other languages
English (en)
French (fr)
Inventor
Shin Miyakawa
Masatoshi Fujiwara
Yoshikazu Nakamura
Original Assignee
Ribomic Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribomic Inc. filed Critical Ribomic Inc.
Priority to JP2009541198A priority Critical patent/JPWO2009063998A1/ja
Publication of WO2009063998A1 publication Critical patent/WO2009063998A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

　ミッドカインに結合し、その活性を阻害する疎水性物質付加核酸およびそのナノ粒子を提供すること。 　ミッドカインに結合し、その活性を阻害する疎水性物質付加核酸およびそのナノ粒子；さらにプレイオトロフィンに対する結合活性を有することを特徴とする核酸；当該核酸および機能性物質（例えば、親和性物質、標識用物質、酵素、薬物送達媒体、又は薬物など）を含む複合体；当該核酸あるいは複合体を含む医薬または試薬；当該核酸あるいは複合体を用いることを特徴とするミッドカインの検出方法；当該ナノ粒子の製造方法など。
PCT/JP2008/070822 2007-11-14 2008-11-14 疎水性物質付加核酸及びその使用 WO2009063998A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009541198A JPWO2009063998A1 (ja) 2007-11-14 2008-11-14 疎水性物質付加核酸及びその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007295951 2007-11-14
JP2007-295951 2007-11-14

Publications (1)

Publication Number Publication Date
WO2009063998A1 true WO2009063998A1 (ja) 2009-05-22

Family

ID=40638844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/070822 WO2009063998A1 (ja) 2007-11-14 2008-11-14 疎水性物質付加核酸及びその使用

Country Status (2)

Country Link
JP (1) JPWO2009063998A1 (ja)
WO (1) WO2009063998A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013534521A (ja) * 2010-06-22 2013-09-05 デエヌア・テラプーティック 核酸コンジュゲートのためのエンドソーム溶解剤を用いた最適化ｉｎｖｉｖｏ送達システム
WO2014080997A1 (ja) 2012-11-21 2014-05-30 株式会社リボミック ミッドカインに対するアプタマー及びその用途
JP2014516977A (ja) * 2011-05-27 2014-07-17 アンスティテュ・キュリ 二本鎖切断を模倣するｄｎａ分子と温熱療法との組み合わせによるガンの処置
US10563197B2 (en) 2015-07-23 2020-02-18 Institut Curie Use of a combination of Dbait molecule and PARP inhibitors to treat cancer
WO2020241493A1 (ja) * 2019-05-24 2020-12-03 株式会社リボミック 骨形成や骨代謝の異常に関連する疾患の治療薬

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11504926A (ja) * 1995-05-04 1999-05-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンド複合体
WO2007055378A1 (ja) * 2005-11-14 2007-05-18 Cell Signals Inc. 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
WO2007086881A2 (en) * 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11504926A (ja) * 1995-05-04 1999-05-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンド複合体
WO2007086881A2 (en) * 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
WO2007055378A1 (ja) * 2005-11-14 2007-05-18 Cell Signals Inc. 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9687557B2 (en) 2010-06-22 2017-06-27 Onxeo Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
US10765758B2 (en) 2010-06-22 2020-09-08 Onxeo Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
US9205099B2 (en) 2010-06-22 2015-12-08 Dna Therapeutics Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
US9428538B2 (en) 2010-06-22 2016-08-30 Dna Therapeutics Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
US10363317B2 (en) 2010-06-22 2019-07-30 Onxeo Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
JP2013534521A (ja) * 2010-06-22 2013-09-05 デエヌア・テラプーティック 核酸コンジュゲートのためのエンドソーム溶解剤を用いた最適化ｉｎｖｉｖｏ送達システム
JP2014516977A (ja) * 2011-05-27 2014-07-17 アンスティテュ・キュリ 二本鎖切断を模倣するｄｎａ分子と温熱療法との組み合わせによるガンの処置
JPWO2014080997A1 (ja) * 2012-11-21 2017-01-05 株式会社リボミック ミッドカインに対するアプタマー及びその用途
US9506070B2 (en) 2012-11-21 2016-11-29 Ribomic Inc. Aptamer against midkine and applications thereof
WO2014080997A1 (ja) 2012-11-21 2014-05-30 株式会社リボミック ミッドカインに対するアプタマー及びその用途
US10563197B2 (en) 2015-07-23 2020-02-18 Institut Curie Use of a combination of Dbait molecule and PARP inhibitors to treat cancer
US11162095B2 (en) 2015-07-23 2021-11-02 Institut Curie Use of a combination of Dbait molecule and PARP inhibitors to treat cancer
WO2020241493A1 (ja) * 2019-05-24 2020-12-03 株式会社リボミック 骨形成や骨代謝の異常に関連する疾患の治療薬

Also Published As

Publication number Publication date
JPWO2009063998A1 (ja) 2011-03-31

Similar Documents

Publication Publication Date Title
WO2006094974A3 (en) Chemically defined stabiliser composition
Chong et al. Tuning the permeability of polymer hydrogel capsules: An investigation of cross-linking density, membrane thickness, and cross-linkers
EP4108655A4 (en) LIPID COMPOUNDS, AND LIPID VECTOR, COMPOSITION OF LIPID NUCLEIC ACID NANOPARTICLES AND PHARMACEUTICAL PREPARATION CONTAINING THEM
WO2009063998A1 (ja) 疎水性物質付加核酸及びその使用
WO2008058963A8 (fr) Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
WO2007100905A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
WO2008036658A3 (en) Method and system for controlled infusion of therapeutic substances
BRPI1006215A2 (pt) " anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo "
WO2008003329A3 (en) Nanoparticles for nucleic acid delivery
MY147374A (en) Aptamer against midkine and use thereof
MX2011013374A (es) Aptamero para quimasa y su uso.
WO2008036841A3 (en) Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
WO2007047579A3 (en) A novel therapeutic target for protozoal diseases
WO2010036918A3 (en) Intracellular dna receptor
WO2010107256A3 (en) Method for preparing a site-specific physiologically active polypeptide conjugate
WO2008066507A3 (en) Nanotube devices for targeted delivery of therapeutic molecules
EP2022853A8 (en) Freeze-dried product for transferring nucleic acid, oligonucleic acid or derivative thereof
WO2011122923A3 (en) Long-acting interferon beta formulation using immunoglobulin fragment
WO2008089771A8 (en) Dna controlled assembly of lipid membranes
WO2006112777A3 (en) Uses of rhcc in drug delivery, real filtering, chemical catalysis and production of nanoparticles
BRPI0919268B8 (pt) aptâmero que se liga ao ngf e medicamento
WO2011053065A3 (ko) 카테콜 폴리에틸렌글리콜 유도체와 단백질 또는 펩타이드의 접합체 및 이의 제조방법
WO2009069711A1 (ja) small RNAの取得用担体、取得方法及び取得用試薬
WO2007137679A3 (de) Vorrichtung und substanz zur isolierung von mesenchymalen stammzellen (msc)
WO2007086911A3 (en) Stable nanoparticle formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08849766

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009541198

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08849766

Country of ref document: EP

Kind code of ref document: A1